- Home
- CNSP vs VTAK Comparison
CNSP vs VTAK Comparison
Compare CNSP & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNSP
- VTAK
- Stock Information
- Founded
- CNSP 2017
- VTAK 2002
- Country
- CNSP United States
- VTAK United States
- Employees
- CNSP N/A
- VTAK N/A
- Industry
- CNSP Biotechnology: Pharmaceutical Preparations
- VTAK Medical/Dental Instruments
- Sector
- CNSP Health Care
- VTAK Health Care
- Exchange
- CNSP Nasdaq
- VTAK Nasdaq
- Market Cap
- CNSP 4.0M
- VTAK 4.1M
- IPO Year
- CNSP 2019
- VTAK 2018
- Fundamental
- Price
- CNSP $7.20
- VTAK $2.11
- Analyst Decision
- CNSP Strong Buy
- VTAK
- Analyst Count
- CNSP 1
- VTAK 0
- Target Price
- CNSP $20.00
- VTAK N/A
- AVG Volume (30 Days)
- CNSP 13.8K
- VTAK 30.1K
- Earning Date
- CNSP 11-17-2025
- VTAK 11-13-2025
- Dividend Yield
- CNSP N/A
- VTAK N/A
- EPS Growth
- CNSP N/A
- VTAK N/A
- EPS
- CNSP N/A
- VTAK N/A
- Revenue
- CNSP N/A
- VTAK $730,000.00
- Revenue This Year
- CNSP N/A
- VTAK $822.86
- Revenue Next Year
- CNSP N/A
- VTAK $168.42
- P/E Ratio
- CNSP N/A
- VTAK N/A
- Revenue Growth
- CNSP N/A
- VTAK 82.96
- 52 Week Low
- CNSP $4.93
- VTAK $1.49
- 52 Week High
- CNSP $114.00
- VTAK $15.68
- Technical
- Relative Strength Index (RSI)
- CNSP 46.98
- VTAK 49.03
- Support Level
- CNSP $6.30
- VTAK $1.50
- Resistance Level
- CNSP $7.07
- VTAK $2.40
- Average True Range (ATR)
- CNSP 0.59
- VTAK 0.18
- MACD
- CNSP 0.06
- VTAK 0.01
- Stochastic Oscillator
- CNSP 34.80
- VTAK 66.97
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
About VTAK Catheter Precision Inc.
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.